The European Foundation for the Study of Diabetes (EFSD) and the Pharmaceutical Company Boheringer Ingelheim will subsidize European research projects on this disease to promote and disseminate new knowledge about diabetes.
Both entities have already opened the deadline for submitting applications, which will be closed on April 1.The program will host proposals dedicated to studies related to the regulation of secretion and/or function of non -insulin peptides secreted by the endocrine pancreas and works related to the mechanisms that relate renal insufficiency with cardiovascular disease in type diabetes of type2.
The call is intended for private entities or groups of non -profit entities throughout Europe.Once submitted, the requests will be the subject of a scientific review by a specialized and independent committee, which will review the proposals and evaluate the social interest, the focus and innovation of the projects.
As explained by the executive director of the EFSD, Viktor Joergens, “with this program we will finance basic information projects with a maximum of 100,000 euros in total for those who last up to two years, and with a maximum of 400,000 euros for clinical research projects ofup to three years ”.
For his part, the senior corporate vice president of Medicine of Boehringer Ingelheim, Kalus Dugi, recalled that "diabetes affects more than 371 million people throughout the world and up to 50% of cases still are still not diagnosed."
